Sen-Jam Pharmaceutical has initiated subject enrolment in the Phase II clinical trial of its investigational oral Covid-19 therapy, SJP-002C, in Nepal. 

Since last year, a joint team of researchers from various countries have been working to obtain approvals to begin the trial with the Nepalese authorities. 

These research activities are the result of the collaboration between Sen-Jam, the Duke-NUS Medical School in Singapore, and Duke University School of Medicine and Global Clinical Research, which together formed a group of global scientists.

Subject enrolment in a clinical trial of SJP-002C under a co-development deal with Duke-NUS and Duke University School of Medicine is underway. 

Sen-Jam collaborated with KVK Tech, the largest strategic investor of the company so far, which will offer access to formulation and chemistry, manufacturing, and controls (CMC) for the Covid-19 therapy.

The partnership with the speciality pharmaceutical manufacturing company will help Sen-Jam quickly produce billions of capsules per year. 

KVK-Tech Business Development director Kiran Vepuri said: “We pride ourselves on our commitment to deliver safe, effective, and affordable FDA-approved pharmaceuticals to meet our customers’ needs and ensure that patients have access to high-quality medicines when they need it. 

“Sen-Jam and their talented team of innovators, scientists, and entrepreneurs represent a perfect fit for our culture of excellence and our unwavering focus on delivering value.”

Sen-Jam focuses on repurposing small molecules for the development of new therapies for large unmet needs to enhance clinical outcomes.

In August last year, the company partnered with Duke-NUS Medical School to begin a Phase II trial of SJP-002C for Covid-19 in Nepal.